22481513|t|[The clinical significance of MIBG myocardial scintigraphy in Parkinson disease].
22481513|a|Meta-iodobenzylguanidine (MIBG) myocardial scintigraphy can assess postganglionic presynaptic cardiac sympathetic nerve endings. Reduced cardiac MIBG uptake on MIBG myocardial scintigraphy has been reported in patients with Parkinson disease (PD), dementia with Lewy bodies (DLB), pure autonomic failure (PAF), and familial PD linked to SNCA duplication. This imaging procedure is a sensitive diagnostic tool that might differentiate PD and DLB from other movement disorders from Alzheimer disease (AD). We recently reported cardiac sympathetic denervation in PD, DLB, PAF, and familial PD linked to SNCA duplication which accounts for the reduced cardiac MIBG uptake in these disorders. The patients with PD, DLB, PAF and familial PD linked to SNCA duplication have Lewy bodies in the nervous system, whereas patients with multiple system atrophy (MSA), progressive supranuclear palsy (PSP), corticobasal degeneration, AD, and parkin-associated PD do not. However, in patients with MSA or PSP, cardiac sympathetic denervation was associated with the presence of Lewy bodies in the nervous system. Therefore, cardiac sympathetic denervation is closely related to the presence of Lewy bodies in the wide range of neurodegenerative processes. Thus, we conclude that reduced cardiac MIBG uptake is a potential biomarker for the presence of Lewy bodies in the nervous system. We infer that MIBG myocardial scintigraphy is a noninvasive tool for detecting Lewy bodies during life.
22481513	30	34	MIBG	Chemical	MESH:D019797
22481513	62	79	Parkinson disease	Disease	MESH:D010300
22481513	82	106	Meta-iodobenzylguanidine	Chemical	MESH:D019797
22481513	108	112	MIBG	Chemical	MESH:D019797
22481513	227	231	MIBG	Chemical	MESH:D019797
22481513	242	246	MIBG	Chemical	MESH:D019797
22481513	292	300	patients	Species	9606
22481513	306	323	Parkinson disease	Disease	MESH:D010300
22481513	325	327	PD	Disease	MESH:D010300
22481513	330	355	dementia with Lewy bodies	Disease	MESH:D020961
22481513	357	360	DLB	Disease	MESH:D020961
22481513	363	385	pure autonomic failure	Disease	MESH:D054970
22481513	387	390	PAF	Disease	MESH:D054970
22481513	406	408	PD	Disease	MESH:D010300
22481513	516	518	PD	Disease	MESH:D010300
22481513	523	526	DLB	Disease	MESH:D020961
22481513	538	556	movement disorders	Disease	MESH:D009069
22481513	562	579	Alzheimer disease	Disease	MESH:D000544
22481513	581	583	AD	Disease	MESH:D000544
22481513	642	644	PD	Disease	MESH:D010300
22481513	646	649	DLB	Disease	MESH:D020961
22481513	651	654	PAF	Disease	MESH:D054970
22481513	669	671	PD	Disease	MESH:D010300
22481513	738	742	MIBG	Chemical	MESH:D019797
22481513	774	782	patients	Species	9606
22481513	788	790	PD	Disease	MESH:D010300
22481513	792	795	DLB	Disease	MESH:D020961
22481513	797	800	PAF	Disease	MESH:D054970
22481513	814	816	PD	Disease	MESH:D010300
22481513	849	860	Lewy bodies	Disease	MESH:D020961
22481513	892	900	patients	Species	9606
22481513	906	929	multiple system atrophy	Disease	MESH:D019578
22481513	931	934	MSA	Disease	MESH:D019578
22481513	937	967	progressive supranuclear palsy	Disease	MESH:D013494
22481513	969	972	PSP	Disease	MESH:D013494
22481513	975	1000	corticobasal degeneration	Disease	MESH:D000088282
22481513	1002	1004	AD	Disease	MESH:D000544
22481513	1010	1016	parkin	Gene	5071
22481513	1028	1030	PD	Disease	MESH:D010300
22481513	1051	1059	patients	Species	9606
22481513	1065	1068	MSA	Disease	MESH:D019578
22481513	1072	1075	PSP	Disease	MESH:D013494
22481513	1145	1156	Lewy bodies	Disease	MESH:D020961
22481513	1261	1272	Lewy bodies	Disease	MESH:D020961
22481513	1362	1366	MIBG	Chemical	MESH:D019797
22481513	1419	1430	Lewy bodies	Disease	MESH:D020961
22481513	1468	1472	MIBG	Chemical	MESH:D019797
22481513	1533	1544	Lewy bodies	Disease	MESH:D020961
22481513	Negative_Correlation	MESH:D019797	MESH:D010300
22481513	Negative_Correlation	MESH:D019797	MESH:D020961
22481513	Association	MESH:D010300	5071
22481513	Negative_Correlation	MESH:D019797	MESH:D054970

